Patents by Inventor Philip Moquist

Philip Moquist has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CYTOTOXIC COMPOUNDS AND CONJUGATES THEREOF
    Publication number: 20240123080
    Abstract: Hydrophilic auristatin compounds are described, including Drug-Linker compounds, Ligand-Drug Conjugate compounds, methods of use, and preparations thereof.
    Type: Application
    Filed: August 11, 2023
    Publication date: April 18, 2024
    Inventors: Philip MOQUIST, Svetlana DORONINA, Nicole DUNCAN, Gabriele BLAHNIK-FAGAN, Sharsti SANDALL
  • Drug conjugates with self-stabilizing linkers having improved physiochemical properties
    Patent number: 11944689
    Abstract: Compounds and compositions are disclosed in which a Drug Unit is linked to a targeting Ligand Unit through a self-stabilizing Linker Unit from which a drug compound or active drug moiety is released at the targeted site of action. Methods for treating diseases characterized by the targeted abnormal cells, such as cancer or an autoimmune disease using the compounds and compositions of the invention are also disclosed.
    Type: Grant
    Filed: August 9, 2017
    Date of Patent: April 2, 2024
    Assignee: Seagen Inc.
    Inventor: Philip Moquist
  • Hydrophobic Auristatin F compounds and conjugates thereof
    Patent number: 11857565
    Abstract: Ligand Drug Conjugates of hydrophobically-modified auristatin F compounds that exhibit cytotoxic activities towards targeted cells, including abnormal cells such as cancer cells, that are MDR+ while also exhibiting bystander activities towards nearby cells having lower expression of the moeity targeted by the Conjugate.
    Type: Grant
    Filed: February 20, 2019
    Date of Patent: January 2, 2024
    Assignee: SEAGEN INC.
    Inventors: Svetlana O. Doronina, Philip Moquist
  • Process for the preparation of pegylated drug-linkers and intermediates thereof
    Patent number: 11844839
    Abstract: The present invention provides improved processes for the preparation of auristatin drug-linkers with a PEG unit, as well as intermediates thereof.
    Type: Grant
    Filed: March 24, 2017
    Date of Patent: December 19, 2023
    Assignee: Seagen Inc.
    Inventors: Yunyu Mao, Philip Moquist, Anusuya Choudhury, Wendel Doubleday
  • CAMPTOTHECIN CONJUGATES
    Publication number: 20230381321
    Abstract: Antibody conjugates with camptothecin compounds are described, with methods of use and preparations.
    Type: Application
    Filed: March 16, 2023
    Publication date: November 30, 2023
    Inventors: Ryan LYSKI, Philip MOQUIST, Nicole DUNCAN, Scott JEFFREY
  • Process for the preparation of glucuronide drug-linkers and intermediates thereof
    Patent number: 11730822
    Abstract: The present invention provides improved processes for the preparation of drug-linkers with a ?-glucuronide cleavable unit, as well as intermediates thereof.
    Type: Grant
    Filed: March 23, 2018
    Date of Patent: August 22, 2023
    Assignee: Seagen Inc.
    Inventors: Yunyu Mao, Philip Moquist, Anusuya Choudhury, Wendel Doubleday
  • HYDROPHOBIC AURISTATIN F COMPOUNDS AND CONJUGATES THEREOF
    Publication number: 20210008099
    Abstract: Ligand Drug Conjugates of hydrophobically-modified auristatin F compounds that exhibit cytotoxic activities towards targeted cells, including abnormal cells such as cancer cells, that are MDR+ while also exhibiting bystander activities towards nearby cells having lower expression of the moeity targeted by the Conjugate.
    Type: Application
    Filed: February 20, 2019
    Publication date: January 14, 2021
    Applicant: SEATTLE GENETICS, INC.
    Inventors: Svetlana O. Doronina, Philip Moquist
  • PROCESS FOR THE PREPARATION OF GLUCURONIDE DRUG-LINKERS AND INTERMEDIATES THEREOF
    Publication number: 20200222553
    Abstract: The present invention provides improved processes for the preparation of drug-linkers with a ?-glucuronide cleavable unit, as well as intermediates thereof.
    Type: Application
    Filed: March 23, 2018
    Publication date: July 16, 2020
    Applicant: SEATTLE GENETICS, INC.
    Inventors: Yunyu Mao, Philip Moquist, Anusuya Choudhury, Wendel Doubleday
  • PROCESS FOR THE PREPARATION OF PEGYLATED DRUG-LINKERS AND INTERMEDIATES THEREOF
    Publication number: 20190388546
    Abstract: The present invention provides improved processes for the preparation of auristatin drug-linkers with a PEG unit, as well as intermediates thereof.
    Type: Application
    Filed: March 24, 2017
    Publication date: December 26, 2019
    Applicant: SEATTLE GENETICS, INC.
    Inventors: Yunyu Mao, Philip Moquist, Anusuya Choudhury, Wendel Doubleday
  • DRUG CONJUGATES WITH SELF-STABILIZING LINKERS HAVING IMPROVED PHYSIOCHEMICAL PROPERTIES
    Publication number: 20190167806
    Abstract: Compounds and compositions are disclosed in which a Drug Unit is linked to a targeting Ligand Unit through a self-stabilizing Linker Unit from which a drug compound or active drug moiety is released at the targeted site of action. Methods for treating diseases characterized by the targeted abnormal cells, such as cancer or an autoimmune disease using the compounds and compositions of the invention are also disclosed.
    Type: Application
    Filed: August 9, 2017
    Publication date: June 6, 2019
    Applicant: SEATTLE GENETICS, INC.
    Inventor: Philip Moquist